AR and prostate cancer: A recently developed androgen receptor (AR) antagonist, psalutamide, significantly inhibited proliferation and migration, induced cysteine protease‐dependent apoptosis, and decreased lipid droplet levels in prostate cancer (PCa) cells by modulating the levels of ACL, ACC, FASN, and SREBP1.